Trade Report: Today, Cascadian Therapeutics’ (CASC) Buy Rating Reaffirm at Jefferies Group

Today, Cascadian Therapeutics’ (CASC) Buy Rating Reaffirm at Jefferies Group

Cascadian Therapeutics Inc. (NASDAQ:CASC)‘s stock had its “buy” rating reiterated by analysts at Jefferies Group in a research note issued to investors on Tuesday. They presently have a $3.00 price target on the biopharmaceutical company’s stock. Jefferies Group’s price objective would indicate a potential upside of 194.12% from the stock’s current price.

A number of other analysts have also commented on the company. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, October 4th. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Monday, October 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $3.00.

Cascadian Therapeutics (NASDAQ:CASC) traded down 1.92% during mid-day trading on Tuesday, hitting $1.02. 289,085 shares of the company were exchanged. The firm has a 50 day moving average price of $1.15 and a 200 day moving average price of $1.16. Cascadian Therapeutics has a 12 month low of $0.82 and a 12 month high of $3.75. The stock’s market cap is $138.02 million.

Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.01. Analysts anticipate that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP raised its stake in shares of Cascadian Therapeutics by 944.4% in the third quarter. Susquehanna International Group LLP now owns 250,788 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 280,488 shares during the last quarter. KCG Holdings Inc. raised its position in Cascadian Therapeutics by 204.6% in the third quarter. KCG Holdings Inc. now owns 137,775 shares of the biopharmaceutical company’s stock valued at $226,000 after buying an additional 92,549 shares in the last quarter. ProShare Advisors LLC raised its position in Cascadian Therapeutics by 20.3% in the third quarter. ProShare Advisors LLC now owns 85,070 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 14,378 shares in the last quarter. Northern Trust Corp raised its position in Cascadian Therapeutics by 23.3% in the third quarter. Northern Trust Corp now owns 162,455 shares of the biopharmaceutical company’s stock valued at $267,000 after buying an additional 30,744 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in Cascadian Therapeutics by 1.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,849,475 shares of the biopharmaceutical company’s stock valued at $3,033,000 after buying an additional 23,406 shares in the last quarter. 66.32% of the stock is currently owned by hedge funds and other institutional investors.

About Cascadian Therapeutics

Related posts

Leave a Comment